Randomized clinical trials towards a single‐visit cure for chronic hepatitis C: Oral GSK2878175 and injectable RG‐101 in chronic hepatitis C patients and long‐acting injectable GSK2878175 in healthy participants-Reference-Cited by-同舟云学术

Randomized clinical trials towards a single‐visit cure for chronic hepatitis C: Oral GSK2878175 and injectable RG‐101 in chronic hepatitis C patients and long‐acting injectable GSK2878175 in healthy participants

Published:2020-03-18 Issue:7 Volume:27 Page:699-708
ISSN:1352-0504
Container-title:Journal of Viral Hepatitis
language:en
Short-container-title:J Viral Hepat

Author:

Deng Yanli¹,Campbell Fiona²,Han Kelong¹,Theodore Dickens³,Deeg Mark⁴,Huang Michael⁴,Hamatake Robert³,Lahiri Soumi¹,Chen Shuguang¹,Horvath Gabor⁵,Manolakopoulos Spilios⁶,Dalekos George N.⁷,Papatheodoridis George⁶^ORCID,Goulis Ioannis⁸,Banyai Tivadar⁹,Jilma Bernd¹⁰,Leivers Martin³^ORCID

Affiliation:

1. GlaxoSmithKline Collegeville Pennsylvania USA

2. GlaxoSmithKline Stockley Park Middlesex UK

3. GlaxoSmithKline Research Triangle Park North Carolina USA

4. Regulus Therapeutics Inc. San Diego California USA

5. Buda Hepatology Center Budapest Hungary

6. 2nd Department of Internal Medicine GI‐Liver Unit Hippocratio General Hospital of Athens National and Kapodistrian University of Athens Athens Greece

7. Department of Medicine and Research Laboratory of Internal Medicine Institute of Internal Medicine and Hepatology University Hospital of Larisa Larisa Greece

8. Aristotle University of Thessaloniki Thessaloniki Greece

9. Bekes County Pandy Kalman Hospital Gyula Hungary

10. Department of Clinical Pharmacology Medical University of Vienna Vienna Austria

Publisher

Wiley

Subject

Virology,Infectious Diseases,Hepatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/jvh.13282

Reference14 articles.

1. EASL Recommendations on Treatment of Hepatitis C 2018

2. Difficult‐to‐cure populations with chronic hepatitis c: Vanishing in the direct‐acting antiviral era?

3. Effectiveness of Sofosbuvir, Ledipasvir/Sofosbuvir, or Paritaprevir/Ritonavir/Ombitasvir and Dasabuvir Regimens for Treatment of Patients With Hepatitis C in the Veterans Affairs National Health Care System

4. GSK2878175, a pan-genotypic non-nucleoside NS5B polymerase inhibitor, in healthy and treatment-naïve chronic hepatitis C subjects

5. Towards a single treatment cure for HCV: reformulation of the pan‐genotypic NS5B NNI GSK2878175 as a long acting parenteral (LAP);Leivers M;Hepatology,2016

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. MicroRNAs in Hepatocellular Carcinoma Pathogenesis: Insights into Mechanisms and Therapeutic Opportunities;International Journal of Molecular Sciences;2024-08-29

2. Advances in MicroRNA Therapeutics: from Preclinical to Clinical Studies;Human Gene Therapy;2024-08-16

3. Non-Coding RNA-Targeted Therapy: A State-of-the-Art Review;International Journal of Molecular Sciences;2024-03-24

4. Discovery of novel microRNA mimic repressors of ribosome biogenesis;Nucleic Acids Research;2024-01-09

5. Gene expression inhibitors for the treatment of liver fibrosis: drugs under preclinical and early clinical investigation;Expert Opinion on Investigational Drugs;2023-11-28